Intellex Acquires Expert by Big Village

We're thrilled to announce that Intellex has acquired Expert by Big Village, effective March 22, 2024. This strategic move enhances our capabilities and strengthens our commitment to delivering exceptional solutions to our customers.

Stay tuned for more updates on how this acquisition will benefit our clients and experts.

For inquiries or more information, please contact us at


Expert Details

Molecular Pathology and Novel Solutions to Thrombosis, Cancer, Sepsis, Immunopathology.

ID: 726428 California, USA

Request Expert

Expert has pioneered the identification of the proteins of the Coagulation cascade responsible for Thrombosis, Hemostasis, Disseminated Intravascular Coagulation, Sepsis, Inflammation and the roles in neoplastic cell invasion and metastasis. He was the first to successfully identify and isolate Factor VIII, Hemophiliac factor, vom Willibrand Factor, and Tissue Factor (TF, thromboplastin) the cell surface receptor that initiates and drives the coagulation cascade and its many resulting pathobiologies and clinical disease, accounting for as much as twenty percent of the mortality of the Western world. He produced the monoclonal antibodies (mAbs) to these proteins for research and therapy.

Expert first elucidated the structure:function of TF in thrombosis and sepsis and with selected monoclonal antibodies to completely rescue primates from 100% lethal sepsis. Similar mAbs have been shown to prevent survival of neoplastic cell metastases in vivo.

Expert pioneered analysis immunochemically of the coagulation cascade proteins. Further and current research is mapping the complex molecular pathways of sepsis which is highly influenced and controlled by the intracellular cytoplasmic domain of TF in conjunction with the cell surface Protease Activated Receptors (PARs). Detailed genetic and other interventional strategies are revealing previously unknown molecular pathways responsible for the severe morbidity and mortality of sepsis. Synthetic compounds to intervene as being successfully identified that function well in vivo in animal models of severe sepsis.

These and other aspects of the molecular pathobiology, pathophysiology and therapeutic intervention are in process.

Expert conceived and advanced novel approaches to tumor eradicative therapy independent of tumor type.
The first is Selective Tumor Vascular Thrombosis which specifically targets a modified Tissue Factor (the initating molecule of the coagulation and thrombosis cascades) to only tumor microvasculature which completely thromboses the tumor vasculature producing complete infarctive necrosis of the tumor. This has used two independent designs. The first using monoclonal antibody targeting. The second using peptides linked to modified Tissue Factor which localize only to tumor microvasculature, enabling function of modified Tissue Factor protein to completely thrombosis only the tumor associated vasculature and complete erradication of the tumor independent of tumor type. The clinical safety and specificity of localization has now been evaluated in the first cohort of humans.

The second independent class of cancer chemotherateutics are called PreProDrugs. These depend on the novel cell surface expression, only in tumors, of the only asparaginyl protease in the human genome. This protease is transported by certain integrins to the surface of tumor cells and tumor vascular endothelial cells, which is necessary for invasive property of neoplastic cells and growth of the tumor vasculature to nourish tumor cells. The drugs are cell impermeable and are only converted to cell permeable prodrugs by encounter with the protease:integrin complex. Upon entering cells of the tumor they are converted to fully cytotoxic derivatives that kill all cells in the tumor, and only in the tumor.

Expert was the first to successfully clone and express Tissue Factor, the initiating molecule of the coagulation protease cascade that is responsible for the coagulation, microthrombotic and lethality of acute severe sepsis. with the patents on Tissue Factor and on monoclonal antibodies to it, he demonstrated the rescue of primates from 100% lethality to 0% lethality. This was safe in chimpanzees.
Next more complex molecular pathogenesis of severe sepsis has been discovered where the cell surface domain as well as the cytoplasmic domain initiate and control cell signaling pathways the lead to the vascular permeability of sepsis, The key cell in this innate immune response is the lymph node dendritic cell that directly mediates the vascular injury and lethality.
The precise molecular signaling pathways, intervention, therapeutic drug design, and related issues have permitted profound reversal of disease characteristics and lethality in an array of genetically modified in vivo sepsis models.

Expert has more than fifty years of experience in advancing vascular medicine, vascular biology, and novel therapeutic intervention. He was the first to clone, express and elucidate the structure-function details of Tissue Factor (TF, thromboplastin) the initiating molecule of the coagulation, Hemostasis, Thrombosis cascade and diseases which drives sepsis and its mortality 30-60% of severe sepsis) and initiates or participates in nearly twenty percent of disease driven mortality in the U.S. and Europe. He has devised and advanced monoclonal antibody therapeutic intervention; and has also pioneered tumor specific thrombotic-infarctive necrosis and tumor eradication therapy research. Expert was the first to identify correctly Factor VIII (Hemophiliac Factor) and separately von Willibrand Factor, the most common cause of hemostatic defects.

Expert pioneered the immune response that drives through both innate and adaptive immune responses the coagulation clotting cascade. These responses are major causes of morbidity and mortality of man.

Shortly after the founding of Centocor, Inc., the pioneering venture into monoclonal antibodies and therapy, by Hubert Schoemaker, PhD in 1979, he began to consult Expert in regard to the therapeutic targets and technology. He continued until Centocor was acquired by J&J. Then, he consulted for J&J about generation of monoclonal antibodies, and re-engineered versions, for possible treatment of sepsis and other diseases. Expert consulted from 1982-85 for Eli Lilly on monoclonal antibodies and potential therapeutic interventions in clinical sepsis. Expert was a consultant to Becton-Dickinson 1977-80 on scientific directions, opportunities in new therapeutic discoveries, and related topics to the Chairman and to the CEO and senior management.Expert founded Corvas International, Inc. and was Chairman of the Board 1987-97. The goal was the discovery of new and novel small molecule inhibitors of the thrombogenic cascade, ones that could arrest and/or prevent the thrombotic process safely and effectively. These goals were in part achieved as well as others. Corvas merged into Dendreon later and continues there. Expert is a member of the Scientific Advisory Board of VGX Pharmaceuticals, Inc. This firm is the leader and IP owner of the key intellectual property for DNA vaccines and related immuno-therapeutics. The National Institutes of Health have now funded a large clinical trial for its HIV vaccines. The VGX flu vaccine is approaching clinical trials. VGX aquired Inovio, Inc. for its engineering of instruments for DNA vaccine delivery and is proceeding successfully.


Year Degree Subject Institution
Year: 1957 Degree: MD Subject: Medicine Institution: Stanford University School of Medicine
Year: 1953 Degree: A.B. Subject: Biology Institution: Stanford University

Work History

Years Employer Title Department
Years: 1965 to Present Employer: Undisclosed Title: Professor Department: Immunology and Microbial Sciences
Head of Research Unit funded by National Institutes of Health; Heart, Lung, Blood Institute; other sources.
Years Employer Title Department
Years: 1968 to 1974 Employer: Scripps Clinic and Research Foundation Title: Founder and Head Department: Pathology
Create the Dept. Pathology. Lead formation and direct participation in Anatomic Pathology, laboratory medicine, and initiate and personally perform Nuclear Medicine. This was done with 50% effort, 50% research effort.
Dept. fully developed therefore I decided to resign to conduct research 100% effort.
Years Employer Title Department
Years: 1962 to 1965 Employer: Univ. Calif. Los Angeles (UCLA) Title: Assistant Professor Department: Pathology
Clinical Anatomic Pathology, Surgical Pathology, Dermatopathology. Medical student and MD resident training.
Years Employer Title Department
Years: 1960 to 1962 Employer: US National Academy of Sciences Title: Pathologist and Investigator, Chromosomal Damage Department: Atomic Bomb Casualty Commission, Hiroshima, Japan
Anatomic Pathology of Atomic Bomb Survivors and Controls. Community pathology services. Establish methods for analysis of chromosomal imaging of lymphocytes from Survivors and Control to search for chromosomal breaks.

Required Legal Immigration to Japan and ability in spoken Japanese.

International Experience

Years Country / Region Summary
Years: 1992 to 1996 Country / Region: Belgium Summary: Expert for Corvs International organized a partnership with venture capital from the Belgian government and established an active and productive research unit there.

Career Accomplishments

Associations / Societies
American Society for Clinical Investigation.
American Society for Biochemistry and Molecular Biology.
American Association of Immunologists.
American Society of Hematology.
American Society for Investigative Pathology.
American Association for the Advancement of Science.
International Society on Thrombosis and Haemostasis.
Association of University Pathologists (Pluto Club).
American Heart Association.
The Protein Society.
Association of American Physicians.
North American Vascular Biology Organization.
Molecular Medicine Society.
American Liver Foundation.
American Association for Cancer Research.
Licenses / Certifications
Anatomic Pathology, Japan
American Board of Pathology, 1965.
Special Certification in Immunopathology, 1984.(The First)
Professional Appointments
Chairman, Molecular Biology Consultants, Inc., 1983-
Member, Board of Directors, Corvas International, Inc., 1987-1997
Member, Board of Directors, Apollon, Inc., 1993-1998
Consultant, Centocor
Consultant, Eli Lilly, 1982-85
Consultant, Becton Dickinson, 1977-80
Consultant, J&J
Scientific Advisory Board, Macronex Inc., Durham, NC, 1991-94
Scientific Advisory Board, Institute of Biotechnology and Advanced Molecular Medicine, Philadelphia, PA, 1991
CalBio Summit '92 Board
Director, NuVas, LLC, 1997-2000
Scientific Advisory Board, VGX, Inc.
Section Editor, Journal of Immunology, 1982 1987.
Associate Editor, Hepatology (Founding 1986).
Editor, Thrombosis Research, 1980 1984.
Editorial Board, American Journal of Pathology, 1980 .
Editorial Board, Journal of the Reticuloendothelial Society, 1981 1984.
Editorial Board, Immunopharmacology, Founding 1995.
Scientific Council, Nouvelle Revue Française d'Hématologie, 1983 .
Editorial Board, Fibrinolysis, 1986 .
Editorial Board, Pathology Research and Practice, 1985 .
Editorial Board, FASEB Journal, 1992 .
Editorial Board, Thrombosis and Haemostasis, 1996-2002.
Editorial Advisory Board, Biochemistry, 1997-1999.
Editorial Board, General Pharmacology: The Vascular System, 1999-2004.
Editorial Board, Journal of Thrombosis and Hemostasis
Awards / Recognition
University of Helsinki Medal, 1973.
Lilly Award Lecture, American Association for the Study of Liver Diseases, 1976.
The College de France Medal, 1981.
Lecturer and Visiting Professor, College de France, Paris, 1981.
The Annual Invited Lecture, National Blood Club, Washington, D.C., 1982.
The J.W. McLaughlin Award, University of Texas, 1983.
Inaugural Address, Thrombosis Research Institute, London, 1990.
John A. Lynch Award in Molecular Biology, University of Notre Dame, 1992.
Rous-Whipple Prize, American Society for Investigative Pathology, 1995.
Distinguished Career Award, the International Society for Thrombosis and Haemostasis, Jerusalem, 1995.
Fellow, American Association for the Advancement of Science, 1996.
Member, Institute of Medicine, National Academy of Sciences, 1997.
Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 1997.
Medical / Professional
1957-1958 Intern, Hospital of the University of Pennsylvania, Philadelphia, PA.
1958-1960 Resident, Pathology, UCLA Center for Health Sciences, Los Angeles, CA.
1959-1960 Resident, Hematopathology, UCLA Health Sciences, Los Angeles, CA.
1960 Communicable Disease Center, U.S.P.H.S. Atlanta, GA.
1965-1968 Senior Postdoctoral Fellow, Department of Experimental
Pathology, Scripps Clinic and Research Foundation, La Jolla,
CA. Mentor: Frank J. Dixon, M.D.
1968 Fellow, Nuclear Medicine, Atomic Energy Commission, Oak Ridge, IN.
Publications and Patents Summary
He has 322 published articles, three more being submitted. He has 64 issued patents and additional applications.

Additional Experience

Expert Witness Experience
Testimony before Congress as well as California Legislature. Participation and presentation to governmental groups including "interest" groups in the pharmaceutical, biotechnology and related industries. Advisory Member appointed to the 1993 Presidential Health Care reform program by Clinton. Advisory Member to analysis and possible reorganization of the National Institutes of Health. Testimony and public television support of the reorganization of research support to Universities in Belgium with the President of Belgium. Invited advisory member to the meeting of the German Government on support and direction of Cancer Research, etc.
Training / Seminars
Expert has organized and instructed medical students at UCLA and also with the creation of the Medical School at Univ. Calif. San Diego (UCSD) where he is an Adjunct Professor of Pathology. He teaches PhD, MD,PhD, and MD graduate students in research in Immunology and in the Coagulation, Thombosis and Hemostasis system.
Vendor Selection
Nearly fifty years of leading research programs, laboratories, and clinical operations.
Marketing Experience
Expert has 60 years of involvement in the financial markets, initiating and participating in established large corporate entities (e.g. J&J, Centocor) and more than ten startups in Biotechology and BioMedicine.
Other Relevant Experience
Expert trained in Physics, Chemistry, Electrical Engineering prior to Medical School. Built the Cardiac Bypass and Oxygenator as a Medical Student with which the cardiac defect was repaired with open heart surgery, the second time in history. His experience is diverse and deep in a number of areas with focus on Immunopathology, new opportunities in Thrombosis therapy, new molecular pathways of sepsis mortality and new molecular approaches to cancer therapy.

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/molecular-pathology-and-novel-solutions-to-thrombosis-cancer-sepsis-immunopathology
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=molecular-pathology-and-novel-solutions-to-thrombosis-cancer-sepsis-immunopathology&page=
Loaded Template: single-experts.php